Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peg-interferon Alpha-2a Added to Truvada in HBV-HIV Co-infection
NCT00391638Phase 3Completed
- Sponsor
- ANRS
- Start
- Jan 2007
- Primary completion
- May 2011
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of peginterferon alfa-2a in hepatitis B (HBV), sponsored by ANRS. Primary endpoint: Proportion of patients with seroconversion HBe and HBV DNA below 2.3 log10 copies per ml at Week 72. Started Jan 2007; status: completed.
02
Drugs
peginterferon alfa-2a
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT00391638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00391638.